INTRODUCTION
The benefits of thrombolytic therapy in acute myocardial infarction are now well established (Lipkin & Reid, 1988) . Streptokinase, administered either intravenously or by the intra-coronary route, is one of the drugs most frequently employed for this purpose (Mason, 1981) . Streptokinase is a non-enzymatic protein (47 kD) produced by group C streptococci, and the recommended initial dose in the UK is 250 000 IU, equivalent to 0-5 g protein. The reported frequency of allergic reactions to the drug varies between 1-7% and 18% (McGrath & Patterson, 1984) of which the majority is mild and self-limiting, taking the form of acute immediate-type hypersensitivity reactions (Sharma, Celia & Parisi, 1982) .
We describe a patient with a delayed allergic reaction to streptokinase, administered as part of the therapy of acute myocardial ischaemia. He was of a severe cellulitic infection of his right leg 13 years previously. The history and ECG were consistent with a diagnosis of acute myocardial infarction, and he received thrombolytic therapy with 1-2 x 106 U of streptokinase (Hoechst, Hounslow, UK) by i.v. infusion into a peripheral vein over 1 h. The infusion was uneventful. The ECG reverted to normal, and there was only a small rise in cardiac enzymes; maximum CPK was 20% above the upper limit of normal.
Plasma creatinine was 94 ymoles/l on admission and 85 ymoles/l on the third day, at which time he developed bilateral loin pain, fever, and a rash on his feet and shins, followed by arthralgia in his knees and elbows, and a falling urine output. He presented to Hammersmith Hospital on day 8.
Physical examination revealed him to be generally unwell, with a blood pressure of 140/95, with no postural hypotension, pulse 90 bt/min, and temperature 38-2°C. The rash on his lower extremities was petechial and his knees and elbows were tender with a reduced range of movement, limited by pain. Urine Precipitating antibodies to streptokinase (Kabivitrum, Uxbridge, UK) were demonstrated in the patient's serum initially by simple diffusion in a 1% agarose gel and a quantitative precipitin test. Titration of antigen at a starting concentration of 20000 U/ml (equivalent to 40 mg/ml) in the presence of constant antibody concentration enabled the establishment of optimal proportions for the reaction, and serial dilutions of peak sera in the same test system were used to calibrate a quantitative radial immunodiffusion assay. Antistreptokinase activity was measured in serum obtained from the patient prior to the therapeutic infusion of the drug, and in all subsequent blood samples.
Measurement of antibody affinity
Binding affinity of anti-streptokinase antibodies in the patient's serum was estimated by incubation of serum with various dilutions of the antigen radiolabelled with 1251 to a specific activity of 1 pCi/pg, followed by precipitation at 50% saturated ammonium sulphate (Minden & Farr, 1973) . Bound and free antigen concentrations were measured, and binding affinity calculated from a plot of the logarithmic transformations of Sip's equation. output during the first 24 h after admission was 25 ml. Urinalysis (Ames) revealed + + blood and + + + protein, and urine microscopy showed numerous granular and cellular casts. Plasma creatinine was 460 Mmol/l. Other relevant results were: sodium 135 mmol/l; potassium 4 0 mmol/l; urea 21-6 mmol/l; haemoglobin 13-4 g/dl; white cell count 12-2 x 109/l (normal differential), platelets 243 x 109/l; ESR 80 mm in the first hour; Creactive protein 120 mg/i (normal < 10 mg/l); creatine kinase 370 iU/I; anti-streptolysin 0 titre 200 iU/l. Anti-neutrophil cytoplasmic antibody was negative, and antibodies to GBM were not detected by radio-immunoassay. Skin (Fig. 1) . He was discharged from hospital after 2 weeks, and at follow-up has remained entirely well.
Preparation of a rabbit anti-streptokinase reagent An adult new Zealand white rabbit was immunized with streptokinase. An initial dose of 4 mg in Freund's complete adjuvant was administered subcutaneously, followed by two further doses of 500 mg, I and 2 weeks later, and a boost of 1 mg of the drug at 5 weeks. Following a test bleed, anti-streptokinase activity was confirmed as described above.
Preparation of FITC-conjugated streptokinase Streptokinase was dissolved in 0 25 M sodium carbonate/0 1 M NaCI buffer, pH 9-0, at a concentration of 10 mg/ml; 2 ml streptokinase were incubated overnight with 1 mg FITC (Sigma, Poole, UK) at 4°C. Unlabelled fluorochrome was removed by separation on a PD1O column.
Immunofluorescent staining ofrenal biopsyfor streptokinase and anti-streptokinase Sections were incubated with FITC-streptokinase at concentrations of 0 25 to 500 yg/ml, for I h at room temperature, followed by extensive washing in PBS. Rabbit polyclonal antistreptokinase (prepared as above) was used at dilutions ranging from 1: I to 1:200 to probe for streptokinase in renal biopsy tissue. Incubation was performed overnight at 4°C, followed by incubation with FITC-conjugated swine anti-rabbit antibody (Dako).
Assay for soluble immune complexes Circulating immune complexes in serum were detected using two radioligand binding assays. All incubations were performed in PBS/NaN3 10 mM/BSA 0.2%/EDTA 10 mm, pH 7 2. Polystyrene microtitre plates (Immulon II Removawells, Dynatech) Antigenic complement. Plasma C3 and C4 levels were measured using single radial immunodiffusion in 1-2% CFDagarose gels containing antibody (polyclonal goat anti-human C3, or sheep anti-human C4 (Serotec, Oxford, UK)). CHs was estimated using a standard haemolytic plate assay.
Enumeration of erythrocyte CRI (CD35), C3dg and C4d. Mean numbers of antigen sites on erythrocytes were measured using radioligand-binding assays, as previously described (Hogg et al., 1984) . Monoclonal antibodies to CR-l was E-l 1 (Hogg et al., 1984) (donated by Dr Nancy Hogg, ICRF, Lincoln's Inn Fields, London), to C3dg was Clone 9 (Lachmann et al., 1980 ) (donated by Professor P. J. Lachmann), and to C4d was T2.C5. 12 (donated by Professor G. D. Ross, Chapel Hill, NC). Radiolabelling was performed using Iodogen (Fraker & Speck, 1978) to a measured specific activity of 1-2 uCi/pg.
RESULTS
Anti-streptokinase activity Precipitating antibodies to streptokinase were detected at a titre of 1:8 before challenge with the drug. At the time of presentation with serum sickness and renal failure, 1 week after therapy, the titre had risen 32-fold, falling rapidly co-incident with plasma exchange, immunosuppression, and recovery of renal function (Fig. 2) . The binding affinity of the antibody present in the patient's serum on day 8 was 1 62 x 10" I/mol. Days following SK therapy Fig. 2 Maximal concentration of cryoglobulin was detected on day 9 following streptokinase therapy-corresponding to the peak of the patient's illness. Precipitin lines were observed when the solubilized cryoglobulin was tested against anti-gamma, antikappa, anti-lambda, and anti-C3 antibodies, and against streptokinase. These findings suggested that the cryoprecipitate contained polyclonal IgG with anti-streptokinase activity, and C3. The presence of IgG in the cryoprecipitate was confirmed by SDS-PAGE. In addition, a second, well-defined band approximating to a molecular weight of 48 kD was observed. We suspected that this might indicate the presence of streptokinase (Mr 47-4 kD) in the cryoglobulin (Fig. 3a) . Immunoblotting of the cryoglobulin run on SDS-PAGE, with the patient's own serum known to have maximal anti-streptokinase activity, confirmed hybridisation to the 48-kD band and a number of smaller polypeptides, in a pattern similar to that seen using purified streptokinase on the same gel (Fig. 3b) . In order to confirm that this material was streptokinase, the polyclonal rabbit anti-streptokinase reagent was used to probe the Western blots; results are shown in Fig. 3c, confirming NHS were observed on days 8 and 9 (at the peak of the illness), returning to levels within the normal range 10 days later. Levels of erythrocyte complement receptor type 1 (CR1(CD35)) measured using the monoclonal antibody El were normal (498 molecules/cell) and did not change throughout the illness and recovery period, but both C3dg and C4d were detected on the surface of erythrocytes obtained from the patient on day 8 and day 10 of the illness. The numbers of C3 molecules detected were 309 and 180 on day 8 and day 10, respectively, while 407 and 162 molecules of C4 were detected (normal levels: C3, < 200 molecules/RBC; C4, <400 molecules/RBC). On day 15, 65 molecules of C3 and 93 molecules of C4 were found, and on day 42 of the illness no significant complement fixation could be detected.
Immunofluorescent staining of renal biopsy Neither streptokinase nor anti-streptokinase were detectable in the patient's renal biopsy by indirect immunofluorescence.
DISCUSSION
Circulating immune complexes, detected as a cryoglobulin, comprising anti-streptokinase, streptokinase and C3, were demonstrated in the serum of a patient, coincident with development of a vasculitic rash and serum sickness. These have not been described previously, although there is one report of the formation of an uncharacterized cryoglobulin in a patient who developed an allergic reaction to streptokinase (Totty et al., 1982) . The formation of specific anti-streptokinase antibodies after therapeutic administration of the drug is well described (Gross & Harth, 1962; Mavor et al., 1969; Flute, 1973; McGrath et al., 1985) . However, our patient is unusual in that IgG antistreptokinase antibodies were detectable in his serum before initiation of therapy, the antibody titre rising rapidly after treatment, prior to the development of serum sickness. He had a past history of severe cellulitis, suggestive of streptococcal infection. There are close antigenic similarities between group A streptococci, which include the common human pathogen S. pyogenes, and group C streptococci from which streptokinase is produced (Read & Zabriske, 1981) . It is probable that he was pre-sensitized by a previous streptococcal infection, resulting in the formation of antibodies cross-reactive with streptokinase. He than developed a vigorous secondary immune response when that antigen was administered exogenously.
There are several case reports of allergic reactions to streptokinase therapy which have resulted in a serum sickness type of illness (Mavor et al., 1969; Totty et al., 1982; Alexopoulos, Raine & Cobbe, 1984; Noel et al., 1987) . Transient mild renal impairment has been reported, usually attributed to an 'immune complex nephritis,' but this diagnosis has not been confirmed by renal biopsy in any of these cases. Although the patient described here had evidence of mesangial complement deposition in his renal biopsy, there was no evidence of IgG deposition, and the histological picture was compatible with a diagnosis of acute tubular necrosis, with morphologically normal glomeruli and no evidence of cholesterol embolization.
One possible explanation for these findings may be that ischemic renal damage resulted from local vasospasm. The clinical course of his myocardial ischaemia was extremely mild, and at no time did he develop systemic hypotension which could have precipitated acute tubular necrosis.
The development of a leucocytoclastic vasculitis following streptokinase therapy has also been described previously (Noel et al., 1987 Mannik & Tung, 1979; Couser & Salant, 1980) , whereas in situ formation of apparently similar amounts of complexes, resulted in nephritis (Mauer et al., 1973; Yamamoto & Wilson, 1986 (Kakkar et al., 1969; Kohner et al., 1976; Six, Marbert & Walter, 1976; Baumgartner & Davis, 1982; Marbert, Eichlisberger & Duckert, 1982; Nelson & Timmis, 1984) . It has been suggested that streptokinase skin tests performed 20 min before therapy may be of value in identifying patients at risk of immediate-type allergic reactions to the drug (Dykiewicz et al., 1986) . Such a test proved to be a sensitive and specific indicator of elevated IgE levels to streptokinase, but it was of no value in detecting elevated IgG levels or in predicting delayed allergic reactions to the drug as described in the present report.
With the increasing use of streptokinase, the frequency of both immediate and delayed hypersensitivity reactions may well increase. The possibility that a previous severe streptococcal infection might induce pre-sensitization to the drug, resulting in the formation of IgG antibodies, circulating immune complexes and serum sickness, raises the question whether alternative thrombolytic or other treatment should be considered in patients with a history of such an infection. While measurement of IgG anti-streptokinase levels may be useful in monitoring patients after therapy, at present, no rapid test for IgG antistreptokinase antibodies is available to assess immunity before treatment. Thrombolytic therapy may be life-saving in acute myocardial infarction or pulmonary embolism, and streptococcal infections of the skin and naso-pharynx are very common. On the basis of current evidence, it might therefore be reasonable to consider an alternative thrombolytic agent in patients in whom there is a history suggestive of previous severe streptococcal infection.
